Evaluation to the chemotherapy use in patients with diffuse large B-cell lymphoma

Dirani Dirani, Suharjono, Made Sedana, Siti Wahyuni, Chrismawan Ardianto, Chris Alderman

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Non-Hodgkin lymphoma (NHL) is a large group of primary malignancies of solid lymphoid tissue. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL. DLBCL has an aggressive natural history but responds well to chemotherapy. The objective of this study was to review the use of chemotherapy, identify its side effects, and examine the response to chemotherapy in patients with NHL at Dr. Soetomo General Hospital. This study was a retrospective observational study using secondary data obtained from patients' medical records from 2016 to 2018. Demographic data (age, sex), clinical characteristics, chemotherapy regimens, side effects of chemotherapy, and response to chemotherapy were recorded. Results revealed that of the 43 patients (age ranged from 21 to 80 years) who were included in this study, the prevalence of DLBCL was higher in male patients (74%) and about 44% patients were at stage III. R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine/oncovin, prednisone) (53%) was the most used chemotherapy regimen in this study. A total of 65% of patients showed good responses and 35% showed no response to the therapy. The most common side effect was myelosuppression, including 25% and 8% of the patients having anemia and leukopenia, respectively. R-CHOP is the most used regimen. Most of patients with NHL have a complete response and the predominant side effect is anemia.

Original languageEnglish
Article number20190336
JournalJournal of Basic and Clinical Physiology and Pharmacology
Issue number6
Publication statusPublished - 1 Mar 2020


  • chemotherapy
  • diffuse large B-cell lymphoma
  • drug utilization study
  • non-Hodgkin lymphoma


Dive into the research topics of 'Evaluation to the chemotherapy use in patients with diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this